Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

calyptuspharma.com

Stage

Unattributed | Alive

Total Raised

$2.9M

Last Raised

$2.9M | 4 yrs ago

About Calyptus Pharmaceuticals

Calyptus Pharmaceutical's mission is to improve lives of patients by increasing access and affordability of quality medicines. Its employees and principals empower the healthcare system by delivering pharmaceutical solutions that bridge unmet needs, resolve technological complexity, create accelerated regulatory pathways and overcome market access barriers.

Calyptus Pharmaceuticals Headquarters Location

174 Nassau St #364

Princeton, New Jersey, 08542,

United States

908-720-6049

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Calyptus Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Calyptus Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Calyptus Pharmaceuticals News

Calyptus Pharmaceuticals Announces FDA Approval of Cetrorelix Acetate for Injection, 0.25 mg/vial

Aug 19, 2022

News provided by Share this article Share this article PRINCETON, N.J., Aug. 19, 2022 /PRNewswire/ -- Calyptus Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration ("FDA") granted approval to an Abbreviated New Drug Application (ANDA) for an AP-rated generic version of Cetrotide® (Cetrorelix Acetate for Injection, 0.25 mg/vial) to Calyptus' partner - Akorn Operating Company LLC ("Akorn"). In addition, the FDA granted the Competitive Generic Therapy (CGT) designation, which makes the product eligible for 180 days of CGT market exclusivity for the 0.25 mg/vial dose. Cetrorelix Acetate for Injection, 0.25 mg/vial is indicated for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian stimulation. Calyptus Co-founders - Sujeet Singh, Dr. Puiho Yuen, and Shubhayu Sinharoy said, "As an industry leader in specialty injectable offerings, Akorn is uniquely positioned to launch the product in the U.S. We are excited that this approval will broaden accessibility to medication for patients undergoing controlled ovarian stimulation. This is an important milestone for Calyptus and further validates our impressive track record of selecting and developing complex sterile dosage forms with an eye toward execution, along with our ability to piece together complex supply chains." According to IQVIA™, U.S. sales of Cetrorelix through June 2022 were approximately $63 million with full year U.S. sales projection of approximately $127 million. About Calyptus Calyptus is a pharmaceutical company based in Princeton, N.J., whose mission is to improve lives of patients by increasing access and affordability of quality medicines. Founded in 2017, Calyptus is developing a portfolio of sterile products (generic ANDAs and specialty 505(b)2s) that resolve technological complexity, create accelerated regulatory pathways, bridge unmet medical needs and overcome market access barriers. Additional information is available on Calyptus' website at www.calyptuspharma.com . CONTACT

Calyptus Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Calyptus Pharmaceuticals Rank

  • Where is Calyptus Pharmaceuticals's headquarters?

    Calyptus Pharmaceuticals's headquarters is located at 174 Nassau St, Princeton.

  • What is Calyptus Pharmaceuticals's latest funding round?

    Calyptus Pharmaceuticals's latest funding round is Unattributed.

  • How much did Calyptus Pharmaceuticals raise?

    Calyptus Pharmaceuticals raised a total of $2.9M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.